$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

$lxrx Overview Financials Valuation SEC Filings Company Website

2012 Q1 Form 10-K Financial Statement

#000106282212000010 Filed on March 08, 2012

Income Statement

Concept	2012 Q1	2010 Q4	2009
Revenue	$300.0K	$1.300M	$10.70M
YoY Change	-49.66%	-7.14%	-66.87%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$5.600M	$3.900M	$19.40M
YoY Change	0.0%	-11.36%	-10.19%
% of Gross Profit
Research & Development	$23.04M	$18.30M	$81.24M
YoY Change	-3.7%	-2.66%	-24.22%
% of Gross Profit
Depreciation & Amortization	$1.125M	$1.300M	$6.159M
YoY Change	-13.93%	-7.14%	-22.04%
% of Gross Profit
Operating Expenses	$29.68M	$23.70M	$100.7M
YoY Change	-0.16%	1.72%	-21.91%
Operating Profit	-$29.38M		-$89.96M
YoY Change	0.85%
Interest Expense	$537.0K	-$600.0K	$2.966M
YoY Change	-11.53%	50.0%	64.78%
% of Operating Profit
Other Income/Expense, Net	-$4.000K	$0.00	-$2.550M
YoY Change	-114.81%	-100.0%	21.43%
Pretax Income	-$29.90M	-$23.00M	-$93.42M
YoY Change	1.01%	0.88%	-3.59%
Income Tax	$0.00	$0.00	-$102.0K
% Of Pretax Income
Net Earnings	-$29.87M	-$23.00M	-$82.78M
YoY Change	0.81%	4.55%	7.65%
Net Earnings / Revenue	-9956.0%	-1769.23%	-773.64%
Basic Earnings Per Share
Diluted Earnings Per Share	-$435.9K	-$477.2K	-$3.981M
COMMON SHARES
Basic Shares Outstanding	480.6M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2012 Q1	2010 Q4	2009
SHORT-TERM ASSETS
Cash & Short-Term Investments	$253.2M	$211.1M	$162.1M
YoY Change	34.04%	29.91%	57.23%
Cash & Equivalents	$29.01M	$47.21M	$100.6M
Short-Term Investments	$224.2M	$163.9M	$61.50M
Other Short-Term Assets	$5.143M	$2.883M	$6.800M
YoY Change	51.26%	-54.95%	23.64%
Inventory
Prepaid Expenses
Receivables	$186.0K	$744.0K	$800.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$259.0M	$214.7M	$169.7M
YoY Change	34.05%	26.54%	55.4%
LONG-TERM ASSETS
Property, Plant & Equipment	$45.53M	$53.43M	$58.80M
YoY Change	-12.11%	-9.14%	-9.68%
Goodwill	$44.54M	$44.54M
YoY Change
Intangibles	$53.56M	$53.56M
YoY Change
Long-Term Investments			$0.00
YoY Change			-100.0%
Other Assets	$181.0K	$619.0K	$3.500M
YoY Change	-39.67%	-82.31%	-39.66%
Total Long-Term Assets	$143.8M	$152.1M	$88.10M
YoY Change	-4.26%	72.7%	-42.15%
TOTAL ASSETS
Total Short-Term Assets	$259.0M	$214.7M	$169.7M
Total Long-Term Assets	$143.8M	$152.1M	$88.10M
Total Assets	$402.8M	$366.9M	$257.8M
YoY Change	17.3%	42.31%	-1.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.324M	$3.159M	$5.900M
YoY Change	-3.2%	-46.46%	-25.32%
Accrued Expenses	$13.71M	$6.264M	$5.600M
YoY Change	78.05%	11.86%	-15.15%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.478M	$1.138M	$38.50M
YoY Change	23.17%	-97.04%	3750.0%
Total Short-Term Liabilities	$20.93M	$10.78M	$51.00M
YoY Change	44.37%	-78.87%	140.57%
LONG-TERM LIABILITIES
Long-Term Debt	$23.06M	$27.35M	$28.50M
YoY Change	-14.58%	-4.05%	-3.39%
Other Long-Term Liabilities	$57.17M	$48.78M	$14.80M
YoY Change	-10.39%	229.61%	-1.33%
Total Long-Term Liabilities	$80.23M	$76.13M	$43.30M
YoY Change	-11.64%	75.82%	-2.7%
TOTAL LIABILITIES
Total Short-Term Liabilities	$20.93M	$10.78M	$51.00M
Total Long-Term Liabilities	$80.23M	$76.13M	$43.30M
Total Liabilities	$133.8M	$119.9M	$94.00M
YoY Change	7.83%	27.51%	23.85%
SHAREHOLDERS EQUITY
Retained Earnings	-$819.5M	-$673.4M
YoY Change
Common Stock	$481.0K	$338.0K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$630.0K	$237.0K
YoY Change
Treasury Stock Shares	380.0K shares	158.0K shares
Shareholders Equity	$269.0M	$247.0M	$163.8M
YoY Change
Total Liabilities & Shareholders Equity	$402.8M	$366.9M	$257.8M
YoY Change	17.3%	42.31%	-1.41%

Cashflow Statement

Concept	2012 Q1	2010 Q4	2009
OPERATING ACTIVITIES
Net Income	-$29.87M	-$23.00M	-$82.78M
YoY Change	0.81%	4.55%	7.65%
Depreciation, Depletion And Amortization	$1.125M	$1.300M	$6.159M
YoY Change	-13.93%	-7.14%	-22.04%
Cash From Operating Activities	-$27.00M	-$19.40M	-$89.02M
YoY Change	25.36%	12.79%	-6.89%
INVESTING ACTIVITIES
Capital Expenditures	$234.0K	-$200.0K	$369.0K
YoY Change	-53.85%	100.0%	-116.77%
Acquisitions			$0.00
YoY Change
Other Investing Activities	-$129.3M	-$144.8M	$12.20M
YoY Change	2593.75%	-24233.33%	-92.45%
Cash From Investing Activities	-$129.6M	-$145.1M	$11.88M
YoY Change	2336.54%	-24283.33%	-92.55%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$233.0K		-$55.35M
YoY Change	-548.08%
Debt Paid & Issued, Net	$353.0K		$2.120M
YoY Change	24.3%
Cash From Financing Activities	-$722.0K	-200.0K	$91.82M
YoY Change	211.21%	-100.37%	-10302.22%
NET CHANGE
Cash From Operating Activities	-$27.00M	-19.40M	-$89.02M
Cash From Investing Activities	-$129.6M	-145.1M	$11.88M
Cash From Financing Activities	-$722.0K	-200.0K	$91.82M
Net Change In Cash	-$157.3M	-164.7M	$14.68M
YoY Change	480.65%	-534.56%	-76.66%
FREE CASH FLOW
Cash From Operating Activities	-$27.00M	-$19.40M	-$89.02M
Capital Expenditures	$234.0K	-$200.0K	$369.0K
Free Cash Flow	-$27.24M	-$19.20M	-$89.39M
YoY Change	23.54%	12.28%	-4.3%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2011Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6042000	USD
CY2010Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3159000	USD
CY2011Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	350000	USD
CY2010Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	744000	USD
CY2011Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13786000	USD
CY2010Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6264000	USD
CY2010Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	80323000	USD
CY2011Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	80535000	USD
CY2010Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	5000	USD
CY2011Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	21000	USD
CY2010Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	920324000	USD
CY2011Q4	us-gaap	Assets Current AssetsCurrent	285790000	USD
CY2010Q4	us-gaap	Assets Current AssetsCurrent	214738000	USD
CY2011Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1087033000	USD
CY2010	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5116000	USD
CY2011	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5707000	USD
CY2009	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5639000	USD
CY2011Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	35000	USD
CY2010Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	35000	USD
CY2011Q4	us-gaap	Assets Assets	430512000	USD
CY2010Q4	us-gaap	Assets Assets	366884000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	186309000	USD
CY2010Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	47208000	USD
CY2009Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	100554000	USD
CY2008Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	85873000	USD
CY2011	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	139101000	USD
CY2009	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	14681000	USD
CY2010	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-53346000	USD
CY2011Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2010Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2010Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2011Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2010Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2011Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2010Q4	us-gaap	Common Stock Value CommonStockValue	338000	USD
CY2011Q4	us-gaap	Common Stock Value CommonStockValue	480000	USD
CY2010	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-101770000	USD
CY2011	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-116199000	USD
CY2009	us-gaap	Contracts Revenue ContractsRevenue	9334000	USD
CY2011	us-gaap	Contracts Revenue ContractsRevenue	1632000	USD
CY2010	us-gaap	Contracts Revenue ContractsRevenue	4191000	USD
CY2010Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	214000	USD
CY2011Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	119000	USD
CY2010Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	14212000	USD
CY2011Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	14212000	USD
CY2011Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	18745000	USD
CY2010Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	18745000	USD
CY2010	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5394000	USD
CY2009	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6159000	USD
CY2011	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4887000	USD
CY2011	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.34
CY2009	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.57
CY2010	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.34
CY2011	us-gaap	Gain Loss On Investments GainLossOnInvestments	0	USD
CY2009	us-gaap	Gain Loss On Investments GainLossOnInvestments	1173000	USD
CY2010	us-gaap	Gain Loss On Investments GainLossOnInvestments	141000	USD
CY2009	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	19418000	USD
CY2011	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17350000	USD
CY2010	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	19396000	USD
CY2011Q4	us-gaap	Goodwill Goodwill	44543000	USD
CY2010Q4	us-gaap	Goodwill Goodwill	44543000	USD
CY2009	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	436000	USD
CY2010	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	1001000	USD
CY2011	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	704000	USD
CY2009	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-93419000	USD
CY2011	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-116215000	USD
CY2010	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-101801000	USD
CY2010	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-26000	USD
CY2011	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2009	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-102000	USD
CY2009	us-gaap	Income Taxes Paid IncomeTaxesPaid	-102000	USD
CY2011	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2010	us-gaap	Income Taxes Paid IncomeTaxesPaid	-26000	USD
CY2009	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2794000	USD
CY2011	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-10365000	USD
CY2010	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	5238000	USD
CY2010	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-488000	USD
CY2009	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	247000	USD
CY2011	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-394000	USD
CY2011	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	95000	USD
CY2010	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	728000	USD
CY2009	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	4730000	USD
CY2009	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	104000	USD
CY2011	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	414000	USD
CY2010	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-218000	USD
CY2009	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-869000	USD
CY2011	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-865000	USD
CY2010	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	6704000	USD
CY2011	us-gaap	Indefinite Lived Intangible Assets Acquired During Period IndefiniteLivedIntangibleAssetsAcquiredDuringPeriod	0	USD
CY2009	us-gaap	Indefinite Lived Intangible Assets Acquired During Period IndefiniteLivedIntangibleAssetsAcquiredDuringPeriod	0	USD
CY2010	us-gaap	Indefinite Lived Intangible Assets Acquired During Period IndefiniteLivedIntangibleAssetsAcquiredDuringPeriod	43557000	USD
CY2011	us-gaap	Interest Expense InterestExpense	2528000	USD
CY2010	us-gaap	Interest Expense InterestExpense	2719000	USD
CY2009	us-gaap	Interest Expense InterestExpense	2966000	USD
CY2011	us-gaap	Interest Paid Net InterestPaidNet	2447000	USD
CY2010	us-gaap	Interest Paid Net InterestPaidNet	2424000	USD
CY2009	us-gaap	Interest Paid Net InterestPaidNet	2519000	USD
CY2009	us-gaap	Investment Income Interest InvestmentIncomeInterest	880000	USD
CY2010	us-gaap	Investment Income Interest InvestmentIncomeInterest	519000	USD
CY2011	us-gaap	Investment Income Interest InvestmentIncomeInterest	255000	USD
CY2010Q4	us-gaap	Liabilities Liabilities	119860000	USD
CY2011Q4	us-gaap	Liabilities Liabilities	132944000	USD
CY2010Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	366884000	USD
CY2011Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	430512000	USD
CY2010Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10775000	USD
CY2011Q4	us-gaap	Liabilities Current LiabilitiesCurrent	21390000	USD
CY2009	us-gaap	Licenses Revenue LicensesRevenue	1366000	USD
CY2010	us-gaap	Licenses Revenue LicensesRevenue	717000	USD
CY2011	us-gaap	Licenses Revenue LicensesRevenue	217000	USD
CY2011Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1443000	USD
CY2010Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1138000	USD
CY2010Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	27345000	USD
CY2011Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	23451000	USD
CY2010	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	142866000	USD
CY2011	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	157084000	USD
CY2009	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	91820000	USD
CY2009	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	11877000	USD
CY2011	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	69955000	USD
CY2010	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-113844000	USD
CY2010	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-82368000	USD
CY2011	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-87938000	USD
CY2009	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-89016000	USD
CY2010	us-gaap	Net Income Loss NetIncomeLoss	-101775000	USD
CY2011	us-gaap	Net Income Loss NetIncomeLoss	-116215000	USD
CY2009	us-gaap	Net Income Loss NetIncomeLoss	-82780000	USD
CY2009	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-10537000	USD
CY2011	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	USD
CY2010	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	USD
CY2010	us-gaap	New Accounting Pronouncement Or Change In Accounting Principle Cumulative Effect Of Change On Equity Or Net Assets NewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets	-1456000	USD
CY2009	us-gaap	Operating Expenses OperatingExpenses	100656000	USD
CY2010	us-gaap	Operating Expenses OperatingExpenses	100626000	USD
CY2011	us-gaap	Operating Expenses OperatingExpenses	115944000	USD
CY2010	us-gaap	Operating Income Loss OperatingIncomeLoss	-95718000	USD
CY2009	us-gaap	Operating Income Loss OperatingIncomeLoss	-89956000	USD
CY2011	us-gaap	Operating Income Loss OperatingIncomeLoss	-114095000	USD
CY2011Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3748000	USD
CY2010Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2883000	USD
CY2010Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	619000	USD
CY2011Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	205000	USD
CY2010	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	5000	USD
CY2011	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	16000	USD
CY2011Q4	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	53557000	USD
CY2010Q4	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	53557000	USD
CY2010Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	48783000	USD
CY2011Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	55146000	USD
CY2010	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4024000	USD
CY2011	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	153000	USD
CY2009	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2550000	USD
CY2009	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	88000	USD
CY2010	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	149000	USD
CY2011	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	108000	USD
CY2011	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2009	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2010	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	5561000	USD
CY2009	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	59955000	USD
CY2010	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	155856000	USD
CY2011	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	108092000	USD
CY2009	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	369000	USD
CY2011	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1206000	USD
CY2010	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1132000	USD
CY2011Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2010Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2010Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2011Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2010Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2011Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2011Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2010Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2011Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2010Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2011	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	160781000	USD
CY2010	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	181496000	USD
CY2009	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	55436000	USD
CY2011	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2009	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	38592000	USD
CY2010	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	11377000	USD
CY2011	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	176628000	USD
CY2010	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	48641000	USD
CY2009	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	60901000	USD
CY2010	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	64000	USD
CY2009	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	107000	USD
CY2011	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	2625000	USD
CY2009	us-gaap	Profit Loss ProfitLoss	-93317000	USD
CY2010	us-gaap	Profit Loss ProfitLoss	-101775000	USD
CY2011	us-gaap	Profit Loss ProfitLoss	-116215000	USD
CY2010Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	53427000	USD
CY2011Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	46417000	USD
CY2009	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	2120000	USD
CY2011	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	3589000	USD
CY2010	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	49858000	USD
CY2010	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	78520000	USD
CY2009	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	81238000	USD
CY2011	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	91828000	USD
CY2010Q4	us-gaap	Restricted Investments RestrictedInvestments	430000	USD
CY2011Q4	us-gaap	Restricted Investments RestrictedInvestments	430000	USD
CY2010Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-673406000	USD
CY2011Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-789621000	USD
CY2011	us-gaap	Revenues Revenues	1849000	USD
CY2010	us-gaap	Revenues Revenues	4908000	USD
CY2009	us-gaap	Revenues Revenues	10700000	USD
CY2011	us-gaap	Share Based Compensation ShareBasedCompensation	5707000	USD
CY2010	us-gaap	Share Based Compensation ShareBasedCompensation	5478000	USD
CY2009	us-gaap	Share Based Compensation ShareBasedCompensation	5274000	USD
CY2010Q4	us-gaap	Short Term Investments ShortTermInvestments	163903000	USD
CY2011Q4	us-gaap	Short Term Investments ShortTermInvestments	95383000	USD
CY2010	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	181474000	USD
CY2009	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	55172000	USD
CY2011	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	160592000	USD
CY2009	lxrx	Purchases Of Investments Held By Symphony Icon Inc PurchasesOfInvestmentsHeldBySymphonyIconInc	4250000	USD
CY2011	lxrx	Shares Used In Computing Net Loss Attributable To Lexicon Pharmaceuticals Inc Per Common Share Basic And Diluted SharesUsedInComputingNetLossAttributableToLexiconPharmaceuticalsIncPerCommonShareBasicAndDiluted	340761000	shares
CY2011	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	363000	USD
CY2010	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	22000	USD
CY2009	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	264000	USD
CY2011	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	189000	USD
CY2010Q4	us-gaap	Stockholders Equity StockholdersEquity	247024000	USD
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	297568000	USD
CY2010Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	247024000	USD
CY2009Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	163497000	USD
CY2011Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	297568000	USD
CY2008Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	195827000	USD
CY2010Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	158000	shares
CY2011Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	218000	shares
CY2010Q4	us-gaap	Treasury Stock Value TreasuryStockValue	237000	USD
CY2011Q4	us-gaap	Treasury Stock Value TreasuryStockValue	345000	USD
CY2011	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	-108000	USD
CY2010	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	-149000	USD
CY2009	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	-88000	USD
CY2011	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	16000	USD
CY2009	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	0	USD
CY2010	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	5000	USD
CY2009	lxrx	Amortization Of Symphony Icon Inc Purchase Option AmortizationOfSymphonyIconIncPurchaseOption	2141000	USD
CY2010	lxrx	Amortization Of Symphony Icon Inc Purchase Option AmortizationOfSymphonyIconIncPurchaseOption	3957000	USD
CY2011	lxrx	Amortization Of Symphony Icon Inc Purchase Option AmortizationOfSymphonyIconIncPurchaseOption	0	USD
CY2010	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	2710000	USD
CY2009	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	0	USD
CY2011	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	6766000	USD
CY2010	lxrx	Deconsolidation Of Symphony Icon Inc DeconsolidationOfSymphonyIconInc	290000	USD
CY2009	lxrx	Maturities Of Investments Held By Symphony Icon Inc MaturitiesOfInvestmentsHeldBySymphonyIconInc	15443000	USD
CY2011	lxrx	Maturities Of Investments Held By Symphony Icon Inc MaturitiesOfInvestmentsHeldBySymphonyIconInc	0	USD
CY2010	lxrx	Maturities Of Investments Held By Symphony Icon Inc MaturitiesOfInvestmentsHeldBySymphonyIconInc	0	USD
CY2011	lxrx	Purchases Of Investments Held By Symphony Icon Inc PurchasesOfInvestmentsHeldBySymphonyIconInc	0	USD
CY2010	lxrx	Purchases Of Investments Held By Symphony Icon Inc PurchasesOfInvestmentsHeldBySymphonyIconInc	0	USD
CY2010	lxrx	Shares Used In Computing Net Loss Attributable To Lexicon Pharmaceuticals Inc Per Common Share Basic And Diluted SharesUsedInComputingNetLossAttributableToLexiconPharmaceuticalsIncPerCommonShareBasicAndDiluted	302844000	shares
CY2011	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2011	dei	Entity Registrant Name EntityRegistrantName	LEXICON PHARMACEUTICALS, INC./DE
CY2011	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2009	lxrx	Shares Used In Computing Net Loss Attributable To Lexicon Pharmaceuticals Inc Per Common Share Basic And Diluted SharesUsedInComputingNetLossAttributableToLexiconPharmaceuticalsIncPerCommonShareBasicAndDiluted	145465000	shares
CY2009	lxrx	Stock Based Compensation Expense Associated With General And Administrative Expense StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense	2252000	USD
CY2010	lxrx	Stock Based Compensation Expense Associated With General And Administrative Expense StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense	2308000	USD
CY2011	lxrx	Stock Based Compensation Expense Associated With General And Administrative Expense StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense	2458000	USD
CY2011	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	3249000	USD
CY2009	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	3022000	USD
CY2010	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	3170000	USD
CY2011	dei	Amendment Flag AmendmentFlag	false
CY2011	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2011	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2011	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2011
CY2011	dei	Document Period End Date DocumentPeriodEndDate	2011-12-31
CY2011	dei	Document Type DocumentType	10-K
CY2011	dei	Entity Central Index Key EntityCentralIndexKey	0001062822
CY2012Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	480560408	shares
CY2011	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2011	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2011Q2	dei	Entity Public Float EntityPublicFloat	229700000	USD

Files In Submission

Name	View Source	Status
0001062822-12-000010-index-headers.html	Edgar Link	pending
0001062822-12-000010-index.html	Edgar Link	pending
0001062822-12-000010.txt	Edgar Link	pending
0001062822-12-000010-xbrl.zip	Edgar Link	pending
a2011graph3.jpg	Edgar Link	pending
exh1010-xnamedexecutiveoff.htm	Edgar Link	pending
exh1015-xofficerstockoptio.htm	Edgar Link	pending
exh1016-xofficerrestricted.htm	Edgar Link	pending
exh105-xlapuertaofferletter.htm	Edgar Link	pending
exh231ernst_youngconsent10.htm	Edgar Link	pending
exh311certificationofprinc.htm	Edgar Link	pending
exh312certificationofprinc.htm	Edgar Link	pending
exh321certificationofprinc.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
form10k12312011.htm	Edgar Link	pending
lxrx-20111231.xml	Edgar Link	completed
lxrx-20111231.xsd	Edgar Link	pending
lxrx-20111231_cal.xml	Edgar Link	unprocessable
lxrx-20111231_def.xml	Edgar Link	unprocessable
lxrx-20111231_lab.xml	Edgar Link	unprocessable
lxrx-20111231_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2012 Q1 Form 10-K Financial Statement

#000106282212000010 Filed on March 08, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2012 Q1 Form 10-K Financial Statement

#000106282212000010 Filed on March 08, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx